Yahoo Finance Today’s Research Reports on Stocks to Watch: Tilray and Cronos
NEW YORK, NY / ACCESSWIRE / September 19, 2018 / Marijuana stocks were rallying on Tuesday after Canadian marijuana cultivator Tilray was given the green light to import marijuana from Canada to the U.S. for a marijuana study. It was also this week that rumors surfaced that Coca-Cola is in talks to get into the marijuana arena. Shares of Tilray and Cronos group were seeing big gains among other marijuana related stocks.
RDI Initiates Coverage on:
Tilray, Inc.
https://www.rdinvesting.com/report/?ticker=TLRY
Cronos Group Inc.
https://www.rdinvesting.com/report/?ticker=CRON
Tilray, Inc. share were seeing more gains in Tuesday's trading session after traders reacted to the U.S. Drug Enforcement Administration signing off on the cannabis cultivator's plan to import a pot product from Canada to test a marijuana's effectiveness at treating a disorder that affects millions of Americans. "Tilray is proud to support this crucial research," says Dr. Catherine Jacobson, Director of Clinical Research at Tilray. "If this study can identify cannabinoids as a potential treatment for patients suffering from essential tremor, we can conduct further research and potentially provide alternative effective methods of relief for the high numbers of patients with Essential Tremor," he continued. The company defines Essential Tremor as a neurological movement disorder characterized by involuntary and rhythmic shaking. “There is no good treatment for essential tremor,” Tilray clinical research director Catherine Jacobson said. “The ultimate goal, what we want to know, is we want to understand whether cannabinoids might be a good treatment.” Shares closed up 28.95% yesterday with an additional 11.63% in after hours trading. Tilray shares hit a new all-time high of $155.10.
Access RDI’s Tilray, Inc. Research Report at:
https://www.rdinvesting.com/report/?ticker=TLRY
Cronos Group Inc. shares closed the day up with 13.56% in gains on Tuesday with even more gains in extended after hours trading. The stock saw its trading volume roughly three times larger than usual yesterday. Marijuana stocks were seeing gains following news that the U.S. Drug Enforcement Administration has approved Canadian marijuana company Tilray's plan to import a marijuana product and test its efficacy in treating a neurological disorder that affects millions of Americans. Earlier this month Cronos announced a partnership with Ginkgo Bioworks. The landmark partnership is to produce cultured cannabinoids. Ginkgo Bioworks, using its platform technology for organism design and development, will complement Cronos Group's technologies for producing a full spectrum of cannabinoids. Cronos Group has agreed to issue a specific number of common shares in tranches subject to Ginkgo's achievement of certain production milestones. "Cronos Group is building the world's most innovative cannabinoid platform," said Mike Gorenstein, CEO of Cronos Group. "The potential uses of cannabinoids are vast, but the key to successfully bringing cannabinoid-based products to market is in creating reliable, consistent, and scalable production of a full spectrum of cannabinoids, not just THC and CBD. We are thrilled to partner with Ginkgo; their biological engineering capabilities and disruptive technology platform are unrivaled. Together we can revolutionize the cannabis industry."
Access RDI’s Cronos Group Inc. Research Report at:
https://www.rdinvesting.com/report/?ticker=CRON
Our Actionable Research on Tilray, Inc. (NASDAQ: TLRY) and Cronos Group Inc. (NASDAQ: CRON) be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
https://www.accesswire.com/512216/Todays-Research-Reports-on-Stocks-to-Watch-Tilray-and-Cronos